Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAmortization of GoodwillAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Change in Accured Expenses (2020 - 2025)

Historic Change in Accured Expenses for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $1.5 million.

  • Maravai Lifesciences Holdings' Change in Accured Expenses rose 24323.56% to $1.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was $8.3 million, marking a year-over-year increase of 15184.03%. This contributed to the annual value of -$22.8 million for FY2024, which is 25060.89% down from last year.
  • Maravai Lifesciences Holdings' Change in Accured Expenses amounted to $1.5 million in Q3 2025, which was up 24323.56% from $5.9 million recorded in Q2 2025.
  • In the past 5 years, Maravai Lifesciences Holdings' Change in Accured Expenses registered a high of $24.2 million during Q1 2023, and its lowest value of -$24.1 million during Q1 2024.
  • Moreover, its 5-year median value for Change in Accured Expenses was $1.5 million (2025), whereas its average is $330947.4.
  • As far as peak fluctuations go, Maravai Lifesciences Holdings' Change in Accured Expenses soared by 88249.85% in 2022, and later crashed by 87077.33% in 2023.
  • Maravai Lifesciences Holdings' Change in Accured Expenses (Quarter) stood at $7.5 million in 2021, then tumbled by 175.11% to -$5.6 million in 2022, then surged by 209.53% to $6.1 million in 2023, then tumbled by 109.4% to -$578000.0 in 2024, then surged by 361.94% to $1.5 million in 2025.
  • Its Change in Accured Expenses stands at $1.5 million for Q3 2025, versus $5.9 million for Q2 2025 and $1.5 million for Q1 2025.